ESPE Abstracts

The development of the artificial pancreas or closed loop for type 1 diabetes, which started as a concept in the last century, took off once continuous glucose monitors became available. The first hybrid closed loop entered the market in 2016, where now several systems compete. This creates the ‘luxury problem’ of having to choose between different systems. Anonymized CGM data collection from company databases try to address the question whether performance in optimized randomized clinical trial circumstances is mirrored in real world evidence, and whether performance is different across the various age groups. Finally, will we soon see fully closed systems, and what would these look like? All this and more will be discussed at the last plenary session of ESPE 2023!